2020 Legislative Priorities
In 2020, our legislative priorities are as aggressive as ALS is.
Legislative Priority 1
Double congressional funding for DOD ALS research from $20 to $40 million and increase NIH ALS research spending by $20 million.
Legislative Priority 2
Make real a funded expanded access program for ALS — providing people living with the disease a pathway to access safe, potentially life-changing therapies ahead of FDA approval.
Legislative Priority 3
Pass the SSDI bill to eliminate the waiting period for ALS patients and their families to receive social security disability benefits.
Legislative Priority 4
Build a Congressional House ALS Caucus to 150 members strong and grow the Congressional Senate ALS Caucus to 25 members.’
Media Contact: Theresa Garner, [email protected]
We will find cures for ALS. The only question is when. That answer depends on you.
Stay informed on I AM ALS’ progress and what you can do to help us make hope real.
Guide to Submitting Written Testimony to the FDA about AMX0035
On September 7, 2022, the FDA will host their second public advisory committee meeting (AdCom) about AMX0035.
ALS Organizations Unite in Support of AMX0035 Approval
ALS Organizations Unite in Support of AMX0035 Approval. Read their open letter.
Response to NINDS ALS Strategic Plan Request for Information
On Feb 10, 2022 I AM ALS submitted a response to the National Insititute of Neurological Disorders and Stroke (NINDS) ALS Strategic Plan Request for Information. NINDS is a part of the National Institute of Health (NIH), which is the largest public funder of ALS research.